D-dimer plasma concentration in chronic urticaria patients with positive autologous serum intradermal test

Advances in Clinical and Experimental Medicine

Volumn 16, Issue 1, 2007, Pages 65-68

  Kasperska Zajac, Alicja ^a   Brzoza, Zenon ^a   Rogala, Barbara ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Autologous serum skin test; D dimer; Fibrinolysis; Urticaria

Indexed keywords

D DIMER;

ADULT; ARTICLE; AUTOIMMUNE SKIN DISEASE; CHRONIC URTICARIA; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; HUMAN; INTRACUTANEOUS TEST; MALE; PROTEIN BLOOD LEVEL; SCREENING TEST;

EID: 33947634114     PISSN: 1230025X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Sabroe RA, Grattan CEH, Francis DM, Barr RM, Kobza Black A, Greaves MW: The autologous serum skin test: a screening test for autoantibodies in chronic idiopathic urticatia. Br J Dermatol 1999, 140, 446-453.
2. Tong LJ, Balakrishnan G, Kochan JP, Kinet JP, Kaplan AP: Assessment of autoimmunity in patients with chronic urticaria. J Allergy Clin Immunol 1997, 99, 461-465.
3. Schwartz LB, Bardford TR, Littman BH, Wintroub BU: The fibrinogenolytic activity of purified tryptase from human lung mast cells. J Immunol 1985, 135, 2762-2767.
4. Valent P, Baghestanian M, Bankl HC, Sillaber C, Sperr WR, Wojta J, Binder BR, Lechner K: New aspects in thrombosis research: possible role of mast cells as profibrinolytic and antithrombotic cells. Thromb Haemost 2002, 87, 786-790.
5. Sillaber C, Baghestanian M, Bevec D, Willheim M, Agis H, Kapiotis S, Füreder W, Bankl HC, Kiener HP, Speiser W, Binder BR, Lechner K, Valent P: The mast cell are site of tissue-type plasminogen activator expression and fibrinolysis. J Immunol 1999, 162, 1032-1041.
6. Kauhanen P, Kovanen PT, Reunala T, Lassila R: Effects of skin mast cells on bleeding time and coagulation activation at the site of platelet plug formation. Thromb Haemost 1998, 79, 843-847.
7. Parslew R, Pryce D, Ashworth J, Friedmann PS: Warfarin treatment of chronic idiopathic urticaria and angio-oedema. Clin Exp Allergy 2000, 30, 1161-1165.
8. Fagiolo U, Cancian M, Bertollo L, Peserico A, Amadori A: Inhibitory effect of heparin on skin reactivity to autologous serum in chronic idiopathic urticaria. J Allergy Clin Immunol 1999, 103, 1143-1147.
9. Chua SL, Gibbs S: Chronic urticaria responding to subcutaneous heparin sodium. Br J Dermatol 2005, 153, 216-217.
10. Lippi G, Volpe A, Caramaschi P, Salvagno GL, Montagnana M, Guidi GC: Plasma D-dimer concentration in patients with systemic sclerosis. Thromb J 2006, 4, 2.
11. Zaryczański J: D-dimery u dzieci chorych na młodzieńcze przewlekłe zapalenie stawów. Reumatologia 1999, 37, 376-382.
12. Inoh M, Tokuda M, Kiuchi H, Kurata N, Takahara J: Evaluating systemic lupus erythematosus disease activity using molecular markers of hemostasis. Arthritis Rheum 1996, 39, 287-291.
13. Zuberbier T, Greaves MW, Juhlin L, Kobza-Black A, Maurer D, Stingl G, Henz BM: Definition, classification, and routine diagnosis of urticaria: a consensus report. J Investig Dermatol Symp Proc 2001, 6, 123-127.
14. Ryan TJ: Urticaria and fibrinolysis. Clin Exp Dermatol 1977, 2, 177-182.
15. Bork K, Witzke G, Artmann K, Benes P, Böckers M, Kreuz W: Interaction between C1-INA, coagulation, fibrinolysis and kinin system in hereditary angioneurotic edema (HANE) and urticaria. Arch Dermatol Res 1984, 276, 375-380.
16. Boonk WJ, Nieboer C, Huijgens PC: Pathogenetic studies in chronic urticaria. Failure to demonstrate vasculitis, complement activation and fibrinolysis. Dermatologia 1986, 173, 264-270.
17. Haustein UF: Fibrinolysis in chronic urticaria. Dermatologia 1987, 175, 51-52.
18. Kasperska-Zajac A, Brzoza Z, Rogala B: The urokinase system in patients with chronic urticaria. Arch Dermatol Res 2007, 298, 409-411.
19. Lip GY, Lowe GD: Fibrin D-dimer: a useful clinical marker of thrombogenesis? Clin Sci 1995, 89, 205-214.
20. Buluk K, Malofiejew M: The pharmacological properties of fibrinogen degradation products. Br J Pharmacol 1969, 35, 78-89.